Can Semax help with autism?
There are no direct studies on Semax and autism spectrum disorder. There are no clinical trials. Likewise, there are no animal models specifically designed to study autism. And no published studies at all link these two topics.
It is worth stating this clearly at the outset. It's easy to come across Semax discussed in relation to autism online and assume that there is some scientific basis for it. Based on the available research, there simply isn't. Nothing in the literature analyses Semax's effects specifically in autism, in animal models of autism, or in any way that would allow this question to be answered with actual evidence.
What evidence is there for Semax and autism?
As there are no direct studies on autism, a reliable answer requires a different approach. We can explore whether known mechanisms of Semax have any theoretical relevance to brain differences associated with autism. However, we must be very careful not to overstate what this theoretical relevance actually means.
The most well-documented mechanism of Semax is a strong increase in BDNF and NGF — growth factors that support neuronal development, synaptic connectivity, and neuroplasticity [1], [2]. Research outside of the Semax literature has explored the role of BDNF in various neurodevelopmental conditions. Some researchers have investigated whether differences in BDNF signalling play a role in autism.
However, the connection „Semax increases BDNF” with „Semax may help with autism” requires several unproven leaps of logic. Firstly, that BDNF differences significantly contribute to autism symptoms in the way sometimes hypothesised. Secondly, that increasing BDNF from outside the body would significantly correct these differences. Thirdly, that this would translate into a beneficial, rather than a neutral or even harmful, effect on autism-related traits specifically. None of these leaps have been tested.
Further documented properties of Semax also touch upon significant biological territory. These include effects on GABA and glutamate receptor systems [3], modulation of serotonin and dopamine activity [4], and anti-inflammatory effects on gene expression [5]. All of these systems have been studied separately in broader research into autism. However, touching upon the same general biological territory as a given condition is very different from having evidence that a compound actually helps with that condition. It would be misleading to present this kind of mechanistic overlap as anything more than a starting point for an untested hypothesis.
Is Semax safe for the autism spectrum?
As there are no studies on Semax in autism, there is also no safety data specific to this population. This is of greater consequence than it might be for some other unstudied uses. The autism spectrum encompasses significant individual variation in neurological function. Some individuals with autism have co-occurring conditions such as epilepsy, far more frequently than the general population. Semax has been associated with EEG changes in at least one clinical population – patients recovering from hypoxia [6]. Given this, and given the complete lack of safety data in autistic individuals of any age, using Semax in this population would represent proceeding essentially without any significant safety information to rely upon.
What do parents and users report about Semax in autism?
Anecdotal reports regarding Semax and autism circulate within some online communities of parents and caregivers. However, these reports are entirely beyond anything that can be scientifically assessed. Parents observing their children may understandably desperately wish to find something that helps. This can make it truly difficult to differentiate a real effect from natural developmental changes, other concurrent interventions, or the very human tendency to notice and remember improvements more than noticing a lack of change. None of this is intended to diminish what any family has experienced. However, it is important to honestly acknowledge that these reports cannot substitute for actual research. Currently, none exist for this specific application.
What would real Semax research in autism look like?
If this were ever to be formally investigated, it would require several things. Properly designed studies with autistic participants. Appropriate autism-specific outcome measures. Careful safety monitoring, given the unique needs of this population. And placebo comparisons. Nothing resembling this has been done.
Given the complete lack of research, Semax currently cannot be recommended, advised against, or significantly discussed as an intervention for autism based on anything more than speculation.
Is Semax safe for teenagers?
No studies have been conducted specifically analysing the safety or effects of Semax in adolescents. This lack of data is a genuine and significant gap, not a minor technicality. Adolescence is a period of significant ongoing brain development. Neural circuits are still actively being wired and pruned during this time. Introducing a compound that significantly alters neurotrophic factor levels and neurotransmitter activity during this developmental window has simply not been studied. There is no way to responsibly extrapolate adult data—already meagre—to the developing adolescent brain.
Existing studies on animal neonates actually reinforce this caution, rather than alleviate it. Semax administered to very young rats during critical developmental windows induced lasting changes in adult behaviour, anxiety levels, and even the number of certain neurons in the brain [7], [8]. These findings tell us something important. Semax can indeed shape brain development when administered during sensitive periods. This is precisely why its use in still-developing adolescents, without any dedicated safety studies in this age group, cannot be responsibly recommended.
Can women use Semax?
Clinical trials involving human subjects for Semax have included women as participants. For example, in a stroke recovery study with 110 patients, 67 participants were women [9]. Therefore, there is no specific documented barrier to its use by women based on sex differences reported in the literature.
However, no study has specifically analysed whether Semax's effects or safety profile differ significantly between men and women. Any gender-specific nuances have simply not been directly investigated.
One area worth particular mention is pregnancy. Several animal studies have actually used Semax in pregnant rats. These studies analysed its effects on offspring following maternal exposure to hypoxia – or oxygen deprivation during pregnancy. Overall protective effects on the developing foetus were found in these specific contexts of stress correction [10], [11]. However, these studies were designed to test whether Semax could correct damage caused by a separate stimulus, namely hypoxia. They were not designed to establish that Semax itself is safe to use during human pregnancy for general purposes. No safety data for human pregnancy exists at all. Pregnant or breastfeeding women should not interpret these animal correction studies as evidence of general safety for voluntary use during pregnancy.
Is Semax safe for the elderly?
The clinical stroke studies that have provided the strongest evidence base for Semax have specifically included older patients. Ischaemic stroke disproportionately affects older adults, so this makes sense. The average age in a study of 110 stroke patients was 58 years [9]. A study of cerebrovascular insufficiency in 187 patients specifically noted good tolerability, including in older age groups. Only a small percentage of adverse effects were reported across the entire study population [12]. This is genuinely reassuring. It means Semax has a real history of clinical use in older adults, including those with significant cerebrovascular disease – arguably a more medically complex population than a healthy younger adult.
However, this data comes from patients treated for a specific medical condition under clinical supervision. It does not come from healthy older individuals voluntarily using Semax for general cognitive support. These two situations are not identical.
Is Semax safe for people with existing medical conditions?
This significantly depends on which state is being considered. A sensible answer for most states is that dedicated studies simply don't exist. For individuals with a history of seizures or epilepsy, extra caution is warranted. This is due to EEG changes documented in at least one patient population [6]. For individuals with clotting disorders or on blood-thinning medication, there is a real, mechanistically grounded reason for concern. Semax has documented anti-clotting and anti-platelet effects – meaning it reduces blood clotting [13]. This is not just a generic „be careful with everything” warning.
For individuals with diabetes or metabolic disorders, studies indicate that Semax influences blood cholesterol and fat levels [14], [15]. These individuals should be aware that metabolic effects may occur, which are worth discussing with a doctor. For most other chronic illnesses – autoimmune diseases, kidney diseases, liver diseases, outside of the specific stress models studied – there are simply no studies analysing whether Semax is safe in this context. The responsible stance is to acknowledge this gap, rather than to assume safety by default.
Kto nie powinien stosować Semax?
Based on all that has been discussed above, several groups should exercise the greatest caution. Some should avoid Semax entirely without direct medical guidance. This includes pregnant and breastfeeding women, given the complete lack of human pregnancy safety data. It includes children and adolescents, given concern for ongoing brain development and the complete lack of paediatric safety studies. It includes individuals with seizure disorders, given the EEG findings in at least one population. It includes individuals taking blood-thinning medications or with clotting disorders, given Semax's own anti-clotting properties. And it includes anyone with a known hypersensitivity to peptide compounds generally.
This is not a list built from formal contraindication data from a regulatory body. Semax has not undergone this type of formal review in Western markets. This is a list built from a careful reading of what the actual research says and does not say, applied with reasonable caution.
Can Semax help with bipolar disorder?
No studies have analysed Semax in individuals with bipolar disorder. This is an area where caution is particularly warranted, given what is known about the pharmacological profile of this compound. Semax has documented dopamine-potentiating effects. It does not release dopamine directly on its own. However, it significantly enhances the dopaminergic response to other stimuli [4], [16]. Bipolar disorder, particularly the manic phase, is closely linked with dysregulated dopamine signalling. There is a genuine, biologically plausible concern here. A compound that potentiates dopaminergic responses could theoretically destabilise the mood in someone predisposed to mania. This has, however, never actually been tested.
There is also something else to consider. Semax also shows serotonergic activation [4] and antidepressant-like effects documented in animal models of stress [17]. These properties are already known, in the context of conventional antidepressant drugs, as occasionally inducing manic episodes in individuals with underlying bipolar affective disorder. Taken together, there is a plausible pharmacological reason for genuine caution – not just a generic „we don't know” caveat.
Is Semax safe in bipolar disorder?
Given the complete lack of research, and considering the theoretically concerning overlap of Semax's dopaminergic and serotonergic effects with known mood-destabilising pathways in bipolar disorder, this is a population in which the use of Semax should not be considered without direct psychiatric involvement, possessing a full picture of the individual's clinical situation. This is not an area for self-experimentation.
Does Semax help with brain fog after COVID?
No study has directly examined Semax for post-COVID cognitive symptoms, sometimes referred to as long COVID brain fog. However, it is worth noting that the biological processes believed to underlie this type of persistent, apparent cognitive dysfunction are relevant here. These include ongoing low-grade neuroinflammation, oxidative stress, and impaired neurotrophic support. These are precisely the types of processes that the documented mechanisms of Semax address in other contexts. The anti-inflammatory effects on gene expression observed in stroke studies [5], [18], and the antioxidant properties demonstrated in numerous models [19], [20], are mechanistically relevant to what we currently understand about the biology of cognitive symptoms post-viral infection.
The mechanistic significance is not, however, proof of efficacy for this particular condition. Until a study is actually conducted in this population, any claim that Semax helps specifically with brain fog following COVID would be speculation masquerading as fact.
Does Semax help with chronic fatigue?
Similarly, no study has analysed Semax specifically for chronic fatigue syndrome or general fatigue complaints. There is some indirect evidence. Semax has demonstrated anti-hypoxic effects, improving resistance to low oxygen conditions in multiple animal studies [21], [22]. It has also shown protective effects on liver function and reduced markers of stress-related organ dysfunction [23]. Fatigue has many possible underlying causes. Some documented effects of Semax do touch upon processes relevant to certain fatigue mechanisms, such as cellular oxygen processing and stress hormone regulation. However, there is no direct evidence linking Semax to significant improvement in chronic fatigue as a defined clinical condition.
In what other conditions could Semax theoretically be beneficial?
Looking at everything documented in studies, Semax's effects extend into truly unexpected corners of physiology beyond the brain. It has demonstrated protective effects on the gastric mucosa against ulcers [24]. It supports healthy gut bacteria populations under stress [25]. It shows protective effects on liver cells during chronic stress [23]. It even influences lipid metabolism relevant to conditions like metabolic syndrome and psoriasis—adding Semax to standard treatment improved cholesterol markers in one clinical trial [15]. It has also shown cardioprotective properties following myocardial infarction in animal models, reducing harmful sympathetic nervous system overactivity and helping to preserve cardiac muscle structure [26], [27].
Neither of them represents a main, well-established application of Semax. These are secondary findings scattered throughout a really broad research programme. They do, however, illustrate something important. The biological reach of Semax extends far beyond the brain-focused nootropic reputation for which it is most known.
What are the established real-world uses of Semax?
Moving away from all speculative and off-label territory, it's worth stating clearly where the evidence for Semax is truly solid. Treatment and rehabilitation following ischaemic stroke. Cerebrovascular insufficiency. And, to a lesser extent, optic nerve disease. These represent uses with actual human clinical trial support [9], [12], [28]. These are also the only conditions for which Semax is actually approved and used clinically, specifically in Russia.
Everything else discussed in this article – autism, ADHD, bipolar disorder, post-COVID symptoms, chronic fatigue – belongs to a completely different category. These are theoretical extrapolations from known Semax mechanisms, not proven clinical benefits for these specific conditions. Being honest about this distinction is important. The gap between „this mechanism seems relevant” and „this compound has been shown to help this condition” is precisely where exaggerated claims usually creep in. It's a gap worth respecting.
Disclaimer
This content is for educational, informational, and scientific purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Semax remains a research compound in most countries, including the United States and most European countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries, specifically for ischaemic stroke, cerebrovascular insufficiency, and optic nerve disease. There are no studies on Semax for autism, bipolar disorder, post-COVID symptoms, chronic fatigue, or use in adolescents. Any individual with a diagnosed medical or psychiatric condition should consult with a qualified healthcare professional before considering Semax and should not alter, discontinue, or substitute any prescribed treatment without medical guidance. Pregnant or breast-feeding women, children, and adolescents should not use Semax outside of formal medical supervision, given the complete lack of safety data in these populations.
References
[1] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
2] Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[3] Sharonova, I. N., Bukanova, Yu. V., Myasoedov, N. F., & Skrebitskii, V. G. (2018). Modulation of GABA- and glycine-activated ionic currents with Semax in isolated cerebral neurons. Bulletin of Experimental Biology and Medicine, 164(5), 612–616. https://doi.org/10.1007/s10517-018-4043-8
[4] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[5] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia–reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[6] Alekseeva, G. V., Bottaev, N. A., & Goroshkova, V. V. (1999). Use of Semax in the follow-up of patients with post-hypoxic encephalopathy. Anaesthesiology and Resuscitation, 40–43. PMID: 10199046
[7] Sebentsova, E. A., Denisenko, A. V., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2005). Long-lasting behavioural effects of chronic neonatal treatment with ACTH (4-10) analogue semax in white rat pups. Journal of Higher Nervous Activity named after I. P. Pavlov, 55(2), 213–220. PMID: 15895862
Boyarshinova, O. S., Revishchin, A. V., Poletaeva, I. I., & Korochkin, L. I. (2004). Neonatal administration of ACTH4-10 and its analog Semax to young laboratory mice modulates the number of catecholaminergic neurons in adult animal diencephalon. Doklady Biological Sciences, 396, 181–183. https://doi.org/10.1023/b:dobs.0000033270.71306.3d
[9] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Maslova, M. V., Graf, A. V., Samoilenkova, N. S., Maklakova, A. S., Sokolova, N. A., & Andreeva, L. A. (2003). Consequences of progestational hypoxia in pregnant rats and its peptide correction (EEG data). Bulletin of Experimental Biology and Medicine, 135(6), 526–529. https://doi.org/10.1023/a:1025404713480
[11] Maslova, M. V., Zemlyanskii, K. S., Shkol’nikova, M. V., Maklakova, A. S., Krushinskaya, Y. V., Sokolova, N. A., & Ashmarin, I. P. (2001). Peptidergic correction of the effect of acute hypobaric hypoxia in pregnant rats on progeny. Bulletin of Experimental Biology and Medicine, 131(2), 109–112. https://doi.org/10.1023/a:1017515206152
[12] Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in the prevention of disease progression and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[13] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulant and antiplatelet effects of semax under conditions of acute and chronic immobilisation stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[14] Elagina, A. A., Lyashev, Yu. D., Lyashev, A. Yu., Pronyaeva, T. V., & Chahine, A. R. (2020). Correction of lipid metabolism disorders in diabetes mellitus with peptide drugs. Bulletin of Experimental Biology and Medicine, 168(5), 618–620. https://doi.org/10.1007/s10517-020-04764-2
[15] Dontsova, E. V. (2015). Possible drug correction of lipid metabolism disturbances associated with metabolic syndrome in patients with psoriasis. Experimental and Clinical Pharmacology, 78(12), 30–33. PMID: 27051926
[16] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
[17] Inozemtseva, L. S., Yatsenko, K. A., Glazova, N. Yu., Kamensky, A. A., Myasoedov, N. F., Levitskaya, N. G., Grivennikov, I. A., & Dolotov, O. V. (2024). Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogues Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 984, 177068. https://doi.org/10.1016/j.ejphar.2024.177068
[18] Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan'kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischaemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
Bashkatova, V. G., Koshelev, V. B., Fadyukova, O. E., Alexeev, A. A., Vanin, A. F., Rayevsky, K. S., Ashmarin, I. P., & Armstrong, D. M. (2001). Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischaemia. Brain Research, 894(1), 145–149. https://doi.org/10.1016/s0006-8993(00)03324-2
[20] Tomasello, M. F., Di Rosa, M. C., Naletova, I., Sciacca, M. F. M., Giuffrida, A., Maccarrone, G., & Attanasio, F. (2025). Semax, a copper chelator peptide, decreases the Cu(II)-catalysed ROS production and cytotoxicity of Aβ by metal ion stripping and redox silencing. Bioinorganic Chemistry and Applications, 2025, 4226220. https://doi.org/10.1155/bca/4226220
[21] Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of Mexidol and Semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550
[22] Kaplan, A. Ia., Koshelev, V. B., Nezavibat’ko, V. N., & Ashmarin, I. P. (1992). Increased resistance to hypoxia effected by the neuropeptide preparation SEMAX. Human Physiology, 18(5), 104–107. PMID: 1335426
[23] Ivanov, A. V., Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Andreeva, L. A., & Myasoedov, N. F. (2017). Influence of ACTG4-7-PGP (Semax) on the morphofunctional state of hepatocytes in chronic emotional and painful stress. Bulletin of Experimental Biology and Medicine, 163(1), 105–108. https://doi.org/10.1007/s10517-017-3748-4
[24] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[25] Svishcheva, M. V., Mukhina, A. Yu., Medvedeva, O. A., Shevchenko, A. V., Bobyntsev, I. I., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2020). Composition of colon microbiota in rats treated with ACTH(4-7)-PGP peptide (Semax) under conditions of restraint stress. Bulletin of Experimental Biology and Medicine, 169(3), 357–360. https://doi.org/10.1007/s10517-020-04886-7
[26] Gavrilova, S. A., Markov, M. A., Berdalin, A. B., Kurenkova, A. D., & Koshelev, V. B. (2017). Changes in sympathetic innervation of the heart in rats with experimental myocardial infarction. Effect of Semax. Bulletin of Experimental Biology and Medicine, 163(5), 617–619. https://doi.org/10.1007/s10517-017-3862-3
[27] Gavrilova, S. A., Golubeva, A. V., Lipina, T. V., Fominykh, E. S., Shornikova, M. V., Postnikov, A. B., Andrejeva, L. A., Chentsov, Yu. S., & Koshelev, V. B. (2006). Protective effect of peptide semax on the rat heart after myocardial infarction. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 92(11), 1305–1321. PMID: 17385423
[28] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of the therapeutic effect of the new Russian drug semax in optic nerve disease. Journal of Ophthalmology, 116(1), 15–18. PMID: 10741256